The rare biomarkers specimen collection and stabilization global market report 2024from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.
Rare Biomarkers Specimen Collection And Stabilization Market, 2024report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.
Market Size – The rare biomarkers specimen collection and stabilization market size has grown rapidly in recent years. It will grow from $29.02 billion in 2023 to $32.01 billion in 2024 at a compound annual growth rate (CAGR) of 10.3%. The growth in the historic period can be attributed to the human genome project, increase in cancer research, pharmaceutical R&D investment, growth of genomics and proteomics, and improved data management and bioinformatics.
The rare biomarkers specimen collection and stabilization market size is expected to see rapid growth in the next few years. It will grow to $47.59 billion in 2028 at a compound annual growth rate (CAGR) of 10.4%. The growth in the forecast period can be attributed to the expansion of liquid biopsy applications, consumer awareness and demand, increasing adoption of non-invasive techniques, and biomarker discovery in rare diseases. Major trends in the forecast period include advancements in preservation technology, growth in genomic and proteomic research, the emergence of point-of-care testing, and regulatory advancements and standardization, enhanced data analytics, and AI integration.
Order your report now for swift delivery @ https://www.thebusinessresearchcompany.com/report/rare-biomarkers-specimen-collection-and-stabilization-global-market-report
Scope Of Rare Biomarkers Specimen Collection And Stabilization Market
The Business Research Company’s reports encompass a wide range of information, including:
- Market Size (Historic and Forecast): Analysis of the market’s historical performance and projections for future growth.
- Drivers: Examination of the key factors propelling market growth.
- Trends: Identification of emerging trends and patterns shaping the market landscape.
- Key Segments: Breakdown of the market into its primary segments and their respective performance.
- Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.
- Macro Economic Factors: Assessment of broader economic elements impacting the market.
Rare Biomarkers Specimen Collection And Stabilization Market Overview
Market Drivers -The increasing prevalence of cancer is expected to propel the growth of the rare biomarker specimen collection and stabilization market going forward. Cancer is a group of diseases defined by the uncontrolled proliferation and spread of abnormal cells. The prevalence of cancer is rising owing to environmental pollutants and lifestyle factors, such as smoking and poor diet choices, exacerbating genetic predispositions. The utilization of rare biomarker specimen collection and stabilization methods in cancer prevalence studies facilitates more accurate detection and monitoring of specific cancer types, enhancing diagnostic and therapeutic approaches. For instance, in October 2023, according to a report by the European Commission, a Europe-based governing body, new cancer cases rose to 2.74 million in 2022, indicating a 2.3% increase from 2020. Therefore, the increasing prevalence of cancer is driving the growth of the rare biomarker specimen collection and stabilization market.
Market Trends – Major companies operating in the rare biomarker specimen collection and stabilization market are focusing on developing innovative solutions, such as a pre-analytical platform to automate the preparation of plasma and cell samples for multiomic liquid biopsy. Pre-analytical platform provides consistent, automated fresh sample preparation at the time of blood collection. It allows for complete walk-away processing of whole blood without the need for special tubes or skilled professionals, therefore preserving sample integrity. For instance, in May 2022, Tethis S.p.A., an Italy-based biotechnology company, launched See.d, the first fully automated, standardized pre-analytical platform that offers unique features such as precise sample handling, efficient separation of plasma for cellular fractions, and fixation of white blood cells on SmartBioSurface slides. The platform features a quality control scoring system for objectively evaluating sample stability. This approach enables the systematic scoring of proteomics and metabolomics data sets to determine the stability of plasma and serum samples.
The rare biomarkers specimen collection and stabilization market covered in this report is segmented –
1) By Type: Circulating Cell Free Deoxyribonucleic Acid (CCFDNA), Circulating Tumor Cells (CTCs), Exosomes or Extracellular Vesicles
2) By Specimen: Serum Or Plasma, Other Specimens
3) By Application: Non-Invasive Prenatal Testing (NIPT), Oncology, Transcriptomics, Pharmacogenomics, Transplant Rejection, Population Screening, Cardiovascular Diseases, Other Applications
4) By End-User: Hospitals, Perinatal Clinics, Public Health Labs, Private Or Commercial Labs, Physician Labs, Research Institutes, Other End-Users
Get an inside scoop of the rare biomarkers specimen collection and stabilization market, Request now for Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=15913&type=smp
Regional Insights – North America was the largest region in the rare biomarkers specimen collection and stabilization market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rare biomarkers specimen collection and stabilization market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Key Companies – Major companies operating in the rare biomarkers specimen collection and stabilization market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Merck KGaA, Becton Dickinson and Company, Eurofins Scientific SE, Agilent Technologies Inc., PerkinElmer Inc., Illumina Inc., Charles River Laboratories International Inc., Bio-Rad Laboratories Inc., Bruker Corporation, QIAGEN N.V., Miltenyi Biotec GmbH, Natera Inc., Promega Corporation, Myriad Genetics, Hamilton Company, OraSure Technologies Inc., Fluidigm Corporation, Streck Inc., SeraCare, Enzo Biochem Inc., Epigenomics AG, Veridex LLC
Table of Contents
1. Executive Summary
2. Rare Biomarkers Specimen Collection And Stabilization Market Characteristics
3. Rare Biomarkers Specimen Collection And Stabilization Market Trends And Strategies
4. Rare Biomarkers Specimen Collection And Stabilization Market – Macro Economic Scenario
5. Global Rare Biomarkers Specimen Collection And Stabilization Market Size and Growth
…………………………….
32. Global Rare Biomarkers Specimen Collection And Stabilization Market Competitive Benchmarking
33. Global Rare Biomarkers Specimen Collection And Stabilization Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Rare Biomarkers Specimen Collection And Stabilization Market
35. Rare Biomarkers Specimen Collection And Stabilization Market Future Outlook and Potential Analysis
36. Appendix
Contact Us:|
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
